Dr Pardoll presents at with AACR 2018 about outcomes from a trial of 20 patients who received anti-PD1 nivolumab before surgical resection. Pathological responses were observed in 45% of patients and, at a median follow-up of 12 months, 16 patients...
Original Article: Results: neoadjuvant nivolumab for resectable lung cancer